|  |
| --- |
| **Box 1: Criteria for a third primary dose of COVID-19 vaccine in those aged 12 years and above** **Individuals with primary or acquired immunodeficiency states at the time of vaccination due to conditions including:** * acute and chronic leukaemias, and clinically aggressive lymphomas (including Hodgkin’s lymphoma) who were under treatment or within 12 months of achieving cure at the time of vaccination
* individuals under follow up for a chronic lymphoproliferative disorders including haematological malignancies such as indolent lymphoma, chronic lymphoid leukaemia, myeloma, Waldenstrom’s macroglobulinemia and other plasma cell dyscrasias (Note: this list is not exhaustive)
* adults and children aged 12 years and over with immunosuppression due to HIV/AIDS with a current CD4 count of <200 cells/*μ*l
* Primary or acquired cellular and combined immune deficiencies – those with lymphopaenia

(<1,000 lymphocytes/*μ*l) or with a functional lymphocyte disorder * those who had received a stem cell transplant or chimaeric antigen receptor (CAR)-T cell therapy in the 24 months before vaccination
* those who had received a stem cell transplant more than 24 months before vaccination but had ongoing immunosuppression or graft versus host disease (GVHD)
* persistent agammaglobulinaemia (IgG < 3g/L) due to primary immunodeficiency (e.g. common variable immunodeficiency) or secondary to disease / therapy

**Individuals on immunosuppressive or immunomodulating therapy at the time of vaccination including:** * those who were receiving immunosuppressive therapy for a solid organ transplant at the time of vaccination
* those who were receiving or had received in the previous 3 months targeted therapy for autoimmune disease, such as JAK inhibitors or biologic immune modulators including B-cell targeted therapies (including rituximab but in this case the recipient would be considered immunosuppressed for a 6 month period), T-cell co-stimulation modulators, monoclonal tumour necrosis factor inhibitors (TNFi), soluble TNF receptors, interleukin (IL)-6 receptor inhibitors., IL-17 inhibitors, IL 12/23 inhibitors, IL 23 inhibitors. (Note: this list is not exhaustive)
* those who were receiving or had received immunosuppressive chemotherapy or radiotherapy for any indication in the 6 months before vaccination

**Individuals with chronic immune-mediated inflammatory disease who were receiving or had received immunosuppressive therapy prior to vaccination including:** * high dose corticosteroids (equivalent to ≥ 20mg prednisolone per day) for more than 10 days in the month before vaccination
* long term moderate dose corticosteroids (equivalent to ≥10mg prednisolone per day for more than 4 weeks) in the 3 months before vaccination
* non-biological oral immune modulating drugs, such as methotrexate >20mg per week (oral and subcutaneous), azathioprine >3.0mg/kg/day; 6-mercaptopurine >1.5mg/kg/day, mycophenolate >1g/day) in the 3 months before vaccination
* certain combination therapies at individual doses lower than above, including those on ≥7.5mg prednisolone per day in combination with other immunosuppressants (other than hydroxychloroquine or sulfasalazine) and those receiving methotrexate (any dose) with leflunomide in the 3 months before vaccination

**Individuals who had received high dose steroids (equivalent to >40mg prednisolone per day for more than a week) for any reason in the month before vaccination** |